Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA)

Clinical and Experimental Immunology

Volumn 150, Issue 1, 2007, Pages 42-48

  Talor, M V ^a   Stone, J H ^a   Stebbing, J ^a   Barin, J ^a   Rose, N R ^a,b   Burek, C L ^a,b,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

ANCA; Bactericidal permeability increasing protein; Cathepsin G; Elastase; Lactoferrin; Myeloperoxidase; Serine protease 3

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CATHEPSIN G; ELASTASE; LACTOFERRIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; SERINE PROTEINASE;

ANCA ASSOCIATED VASCULITIS; ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CHURG STRAUSS SYNDROME; CONTROLLED STUDY; ENTERITIS; ENZYME IMMUNOASSAY; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MICROSCOPIC POLYANGIITIS; PRIORITY JOURNAL; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIMICROBIAL CATIONIC PEPTIDES; AUTOANTIBODIES; AUTOANTIGENS; BLOOD PROTEINS; CATHEPSINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PEROXIDASE; SERINE ENDOPEPTIDASES; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 34548542324     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03453.x     Document Type: Article

References (29)

1. Van Der Woude FJ, Rassmussen N, Lobatto S et al. Autoantibodies to neutrophils and monocytes: a new tool for diagnosis and a marker for disease activity in Wegener's granulomatosis. Lancet 1985 1:425 9.
2. Stone JH, Talor M, Stebbing J et al. Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions. Arthritis Care Res 2000 13:424 34.
3. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988 318:1651 7.
4. Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998 41:1521 37.
5. Savige JA, Davies DJ, Gatenby PA. Anti-neutrophil cytoplasmic antibodies (ANCA). their detection and significance: report from workshops. Pathology 1994 26:186 93.
6. Hohn PA, Popescu NC, Hanson RD, Salvesen G, Ley TJ. Genomic organization and chromosomal localization of the human cathepsin G gene. J Biol Chem 1989 264:13412 19.
7. Calafat J, Janssen H, Knol EF, Malm J, Egesten A. The bactericidal/permeability-increasing protein (BPI) is membrane-associated in azurophil granules of human neutrophils, and relocation occurs upon cellular activation. APMIS 2000 108:201 8.
8. Roos D, Dolman KM. Neutrophil involvement in inflammatory tissue damage. Neth J Med 1990 36:89 94.
9. Gaskin G, Savage CO, Ryan JJ et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991 6:689 94.
10. Tervaert JW, Kallenberg CG. Anti-myeloperoxidase antibodies in Churg-Strauss syndrome. J Neurol 1993 240:449 50.
11. Goldschmeding R, van der Schoot CE, ten Bokkel HD et al. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate- binding protein in the lysosomes of normal human neutrophils. J Clin Invest 1989 84:1577 87.
12. Nassberger L, Jonsson H, Sjoholm AG, Sturfelt G, Heubner A. Circulating anti-elastase in systemic lupus erythematosus. Lancet 1989 1:509.
13. Kuwana T, Sato Y, Saka M et al. Anti-cathepsin G antibodies in the sera of patients with ulcerative colitis. J Gastroenterol 2000 35:682 9.
14. Manolova I, Dantcheva M. Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations. Rheumatol Int 2005 26:107 14.
15. Wiesner O, Russell KA, Lee AS et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 2004 50:2954 65.
16. Nishiya K, Chikazawa H, Hashimoto K, Miyawaki S. Antineutrophil cytoplasmic antibody in patients with primary Sjogren's syndrome. Clin Rheumatol 1999 18:268 71.
17. Coremans IE, Hagen EC, Daha MR et al. Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis. Arthritis Rheum 1992 35:1466 75.
18. Vecchi M, Sinico A, Bianchi MB et al. Recognition of bactericidal/ permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients: prevalence and clinical significance. Scand J Gastroenterol 1998 33:1284 8.
19. Caccavo D, Rigon A, Picardi A et al. Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates. Clin Rheumatol 2005 24:381 7.
20. Xu X, Zhao M, Zhang Y, Guo X, Wang H. [Clinicopathological characteristics of propylthiouracil-induced antineutrophil cytoplasmic antibodies-positive vasculitis and their target antigens: a report of 4 cases and literature review]. Zhonghua Nei Ke Za Zhi 2002 41:404 7.
21. Zhao MH, Jayne DR, Ardiles LG, Culley F, Hodson ME, Lockwood CM. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. Q J Med 1996 89:259 65.
22. Schultz H, Csernok E, Schuster A, Schmitz TS, Ernst M, Gross WL. Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/ permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI. Pediatr Allergy Immunol 2000 11:64 70.
23. Savige JA, Chang L, Wilson D, Buchanan RR. Autoantibodies and target antigens in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Rheumatol Int 1996 16:109 14.
24. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994 37:187 92.
25. Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity 2005 38:93 103.
26. Savige J, Davies D, Falk RJ, Jennette JC, Wiik A. Antineutrophil cytoplasmic antibodies and associated diseases. a review of the clinical and laboratory features. Kidney Int 2000 57:846 62.
27. Haubitz M, Gerlach M, Kruse HJ, Brunkhorst R. Endothelial tissue factor stimulation by proteinase 3 and elastase. Clin Exp Immunol 2001 126:584 8.
28. Yahya TM, Benedict S, Shalabi A, Bayoumi R. Anti-neutrophil cytoplasmic antibody (ANCA) in malaria is directed against cathepsin G. Clin Exp Immunol 1997 110:41 4.
29. Gao Y, Chen MYeH, Guo XH, Zhao MH, Wang HY. The target antigens of antineutrophil cytoplasmic antibodies (ANCA) induced by propylthiouracil. Int Immunopharmacol 2007 7:55 60.